Hepaxane (Enoxaparin Sodium)

Hepaxane is indicated for several antithrombotic purposes in clinical practice, primarily to prevent and treat venous thromboembolism and to provide anticoagulation in acute coronary settings.

• Prevention of deep vein thrombosis (DVT) in patients undergoing orthopedic or general surgery.
• Treatment of acute DVT confirmed by imaging studies.
• Prophylaxis and treatment of pulmonary embolism (PE) in at‑risk individuals.
• Anticoagulation in patients with acute coronary syndromes, including unstable angina and non‑ST‑segment elevation myocardial infarction.
• Use as bridging therapy when transitioning between oral anticoagulants and procedural interventions.

The safety profile of Hepaxane includes a range of observed adverse events, which are generally categorized by frequency and clinical significance.

Common

• Minor bleeding at the injection site, such as bruising or small hematoma.
• Nosebleeds (epistaxis) or gum bleeding that resolves spontaneously.
• Mild gastrointestinal discomfort or nausea.
• Elevated liver enzymes without clinical symptoms.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Thrombocytopenia, particularly heparin‑induced thrombocytopenia (HIT).
• Allergic reactions ranging from rash to anaphylaxis.

Before initiating Hepaxane therapy, clinicians should evaluate several precautionary factors to minimize the risk of complications.

• Assess renal function, as dose adjustment may be required in severe impairment.
• Review patient history for prior heparin exposure or heparin‑induced thrombocytopenia.
• Monitor platelet counts regularly during treatment to detect HIT early.
• Use caution in patients with active bleeding, recent surgery, or traumatic injuries.
• Avoid concurrent use of other anticoagulants or antiplatelet agents unless specifically indicated.
• Consider pregnancy status; the safety profile in pregnant women is not well established.

Hepaxane can interact with several medications, affecting either its anticoagulant effect or the safety of the co‑administered drug.

Avoid

• Concomitant use with other parenteral anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors) due to additive bleeding risk.
• Concurrent administration of potent antiplatelet agents such as clopidogrel or ticagrelor without dose adjustment.
• Use with fibrinolytic therapy (e.g., alteplase) because of heightened hemorrhagic potential.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin, which may increase minor bleeding.
• Certain antibiotics (e.g., vancomycin, aminoglycosides) that can alter platelet function.
• Drugs that affect renal clearance, such as trimethoprim‑sulfamethoxazole, requiring closer monitoring.